Cencora (COR) Q3 (USD): Adj. EPS 4.48 (exp. 4.35), Revenue 84.75bln (exp. 84.31bln)

A modest beat on both lines, of the scale that has historically been treated as routine for the large US drug distributors: the group's earnings tend to be stable and guidance-driven rather than print-driven, since volumes through the wholesale channel are predictable and the swing factors sit in generics mix, GLP-1 distribution flows, and the contribution from specialty and international segments. Prints of this size from the peer set have typically produced contained opening moves unless accompanied by a change to full-year guidance, which is the tell that has mattered in past quarters. The distinction worth drawing is between a beat carried by the core US distribution margin and one carried by below-the-line items or one-offs; the former reads through to peers, the latter does not. The follow-ons are the call commentary on guidance, any update on opioid litigation or fee-for-service contract terms, and whether the read-across lifts the rest of the distributor and pharmacy supply chain complex. As a single-ticker print with a small beat, the signal is incremental rather than thesis-changing.